MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) has filed patent applications covering 15 novel discoveries in AI-driven voice intoxication detection, the company announced. The technology analyzes speech patterns to estimate drug and alcohol impairment without requiring physical samples, potentially revolutionizing testing in high-volume, regulated environments.
The patent applications center on a machine learning model designed to detect impairment using short voice samples. This approach departs from conventional methods that rely on urine, blood, or breath samples, which can be costly and time-consuming. The overall global drug and alcohol testing market is projected to reach $4.2 billion by 2033, according to the company.
Initial commercial rollout is targeting mining and aviation sectors via Edge AI kiosk systems. Broader applications include call centers, law enforcement, and mental health screening. The technology is designed for environments where frequent testing is necessary but traditional methods are impractical.
MindBio Therapeutics is a biotechnology company commercializing AI-driven voice technology for drug and alcohol intoxication detection. The company has moved to formalize its intellectual property position with these filings, which are detailed in a recent company update. For more information, visit the company’s newsroom at https://ibn.fm/MBQIF.
This development matters because it addresses a significant pain point in industries where safety is paramount and testing is mandatory. By enabling rapid, non-invasive screening, the technology could reduce downtime and costs while improving compliance. If successful, it may set a new standard for impairment detection globally.
